Epilepsy Clinical Trial
Official title:
A Multicenter, Open-label, Long-term Extension Study to Investigate the Efficacy and Safety of Lacosamide as Adjunctive Therapy in Pediatric Subjects With Epilepsy With Partial-Onset Seizures
Verified date | September 2022 |
Source | UCB Pharma |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to evaluate the long-term safety, tolerability and efficacy of lacosamide (LCM) in pediatric subjects.
Status | Completed |
Enrollment | 540 |
Est. completion date | April 13, 2022 |
Est. primary completion date | April 13, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 1 Month to 17 Years |
Eligibility | Inclusion Criteria: - An Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved written Informed Consent form (ICF) is signed and dated by the subject or legal representative. The ICF or a specific Assent form, where required, will be signed and dated by minors - Subject has completed the Transition Period of SP0967 [NCT02477839] or SP0969 [NCT01921205] for the treatment of uncontrolled partial-onset seizures in pediatric epilepsy - Subject is expected to benefit from participation, in the opinion of the investigator - Subject/legal representative is considered reliable and capable of adhering to the protocol (eg, able to understand and complete diaries), visit schedule, and medication intake according to the judgment of the investigator - Subject is male or female aged 1 month to =17 years - Subject has a diagnosis of epilepsy with partial-onset seizures Exclusion Criteria: - Subject is receiving any investigational drugs or using any experimental devices in addition to lacosamide (LCM) - Subject meets a mandatory withdrawal criterion (ie, MUST withdraw criterion) for SP0967 or SP0969, or is experiencing an ongoing serious adverse event (SAE) - For subjects =6 years of age, subject has a lifetime history of suicide attempt (including an actual attempt, interrupted attempt, or aborted attempt), or has suicidal ideation in the past 6 months as indicated by a positive response ('Yes') to either Question 4 or Question 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) at Visit 1 - Female subject who is pregnant or nursing, and/or a female subject of childbearing potential who is not surgically sterile or does not practice 1 highly effective method of contraception |
Country | Name | City | State |
---|---|---|---|
Argentina | Ep0034 143 | Ciudad Autonoma de Buenos Aire | |
Argentina | Ep0034 142 | Cordoba | |
Australia | Ep0034 200 | Melbourne | |
Australia | Ep0034 203 | Parkville | |
Australia | Ep0034 205 | South Brisbane | |
Belgium | Ep0034 304 | Brussels | |
Brazil | Ep0034 158 | Passo Fundo | |
Brazil | Ep0034 150 | Sao Paulo | |
Brazil | Ep0034 154 | Sao Paulo | |
Bulgaria | Ep0034 310 | Plovdiv | |
China | Ep0034 530 | Beijing | |
China | Ep0034 535 | Changchun | |
China | Ep0034 532 | Chongqing | |
China | Ep0034 536 | Nanchang | |
China | Ep0034 531 | Shanghai | |
China | Ep0034 537 | Shenzhen | |
Colombia | Ep0034 171 | Medellin | |
Croatia | Ep0034 613 | Osijek | |
Croatia | Ep0034 610 | Rijeka | |
Croatia | Ep0034 612 | Zagreb | |
Czechia | Ep0034 321 | Hradec Kralove | |
Czechia | Ep0034 320 | Ostrava-poruba | |
Czechia | Ep0034 322 | Praha 4 - Krc | |
Czechia | Ep0034 323 | Praha 5 | |
Estonia | Ep0034 331 | Tallinn | |
Estonia | Ep0034 330 | Tartu | |
France | Ep0034 346 | Rennes Cedex 2 | |
France | Ep0034 344 | Strasbourg Cedex | |
Georgia | Ep0034 620 | Tbilisi | |
Georgia | Ep0034 621 | Tbilisi | |
Georgia | Ep0034 622 | Tbilisi | |
Georgia | Ep0034 623 | Tbilisi | |
Greece | Ep0034 542 | Athens | |
Hungary | Ep0034 361 | Budapest | |
Hungary | Ep0034 362 | Budapest | |
Hungary | Ep0034 363 | Budapest | |
Hungary | Ep0034 364 | Budapest | |
Hungary | Ep0034 368 | Budapest | |
Hungary | Ep0034 360 | Debrecen | |
Hungary | Ep0034 367 | Miskolc | |
Hungary | Ep0034 366 | Pecs | |
Israel | Ep0034 374 | Petah Tiqwa | |
Italy | Ep0034 397 | Genova | |
Italy | Ep0034 380 | Mantova | |
Italy | Ep0034 398 | Messina | |
Italy | Ep0034 381 | Milano | |
Italy | Ep0034 393 | Padova | |
Italy | Ep0034 383 | Roma | |
Italy | Ep0034 392 | Roma | |
Italy | Ep0034 395 | Roma | |
Italy | Ep0034 386 | Verona | |
Korea, Republic of | Ep0034 211 | Daegu | |
Korea, Republic of | Ep0034 210 | Seoul | |
Korea, Republic of | Ep0034 212 | Seoul | |
Korea, Republic of | Ep0034 213 | Seoul | |
Korea, Republic of | Ep0034 215 | Seoul | |
Latvia | Ep0034 400 | Riga | |
Latvia | Ep0034 402 | Valmiera | |
Lithuania | Ep0034 411 | Kaunas | |
Mexico | Ep0034 694 | Aguascalientes | |
Mexico | Ep0034 569 | Culiacan | |
Mexico | Ep0034 693 | Culiacan | |
Mexico | Ep0034 563 | Guadalajara | |
Mexico | Ep0034 564 | Mexico | |
Mexico | Ep0034 568 | Monterrey | |
Moldova, Republic of | Ep0034 650 | Chisinau | |
Montenegro | Ep0034 660 | Podgorica | |
Philippines | Ep0034 724 | Cebu | |
Philippines | Ep0034 721 | Manila | |
Poland | Ep0034 433 | Gdansk | |
Poland | Ep0034 420 | Kielce | |
Poland | Ep0034 422 | Krakow | |
Poland | Ep0034 431 | Krakow | |
Poland | Ep0034 423 | Poznan | |
Poland | Ep0034 425 | Poznan | |
Poland | Ep0034 429 | Tyniec Maly | |
Poland | Ep0034 430 | Warszawa | |
Poland | Ep0034 428 | Wroclaw | |
Portugal | Ep0034 750 | Lisbon | |
Romania | Ep0034 574 | Bucuresti | |
Romania | Ep0034 581 | Bucuresti | |
Romania | Ep0034 572 | Cluj-napoca | |
Romania | Ep0034 582 | Iasi | |
Romania | Ep0034 573 | Sibiu | |
Romania | Ep0034 576 | Sibiu | |
Romania | Ep0034 580 | Suceava | |
Romania | Ep0034 570 | Timisoara | |
Romania | Ep0034 577 | Timisoara | |
Russian Federation | Ep0034 450 | Ekaterinburg | |
Russian Federation | Ep0034 443 | Kazan | |
Russian Federation | Ep0034 444 | Kazan | |
Russian Federation | Ep0034 454 | Kemerovo | |
Russian Federation | Ep0034 442 | Moscow | |
Russian Federation | Ep0034 449 | Moscow | |
Russian Federation | Ep0034 456 | Nizhniy Novgorod | |
Russian Federation | Ep0034 452 | Novosibirsk | |
Russian Federation | Ep0034 453 | Omsk | |
Russian Federation | Ep0034 455 | Perm | |
Russian Federation | Ep0034 441 | Saint Petersburg | |
Russian Federation | Ep0034 440 | Smolensk | |
Russian Federation | Ep0034 730 | Smolensk | |
Russian Federation | Ep0034 446 | St. Petersburg | |
Russian Federation | Ep0034 458 | Tomsk | |
Russian Federation | Ep0034 447 | Voronezh | |
Serbia | Ep0034 461 | Belgrade | |
Serbia | Ep0034 464 | Belgrade | |
Serbia | Ep0034 460 | Kragujevac | |
Serbia | Ep0034 462 | Novi Sad | |
Serbia | Ep0034 463 | Novi Sad | |
Slovakia | Ep0034 470 | Bardejov | |
Slovakia | Ep0034 472 | Nove Zamky | |
Slovenia | Ep0034 670 | Ljubljana | |
Taiwan | Ep0034 220 | Changhua City | |
Taiwan | Ep0034 222 | Taichung | |
Taiwan | Ep0034 224 | Taipei | |
Thailand | Ep0034 236 | Bangkoknoi | |
Thailand | Ep0034 235 | Pathum Wan | |
Thailand | Ep0034 230 | Ratchathewi | |
Thailand | Ep0034 232 | Ratchathewi | |
Thailand | Ep0034 231 | Tha Muang | |
Thailand | Ep0034 233 | Tha Muang | |
Ukraine | Ep0034 602 | Dnipro | |
Ukraine | Ep0034 609 | Dnipro | |
Ukraine | Ep0034 681 | Ivano-frankivsk | |
Ukraine | Ep0034 600 | Kiev | |
Ukraine | Ep0034 606 | Kiev | |
Ukraine | Ep0034 682 | Uzhgorod | |
Ukraine | Ep0034 603 | Vinnytsia | |
United Kingdom | Ep0034 515 | Cambridge | |
United Kingdom | Ep0034 511 | Leeds | |
United States | Ep0034 638 | Birmingham | Alabama |
United States | Ep0034 102 | Charlotte | North Carolina |
United States | Ep0034 129 | Dallas | Texas |
United States | Ep0034 115 | Henderson | Nevada |
United States | Ep0034 120 | Lebanon | New Hampshire |
United States | Ep0034 124 | Lexington | Kentucky |
United States | Ep0034 105 | Orlando | Florida |
United States | Ep0034 630 | San Antonio | Texas |
United States | Ep0034 114 | Seattle | Washington |
United States | Ep0034 640 | Springfield | Oregon |
United States | Ep0034 117 | Tampa | Florida |
Lead Sponsor | Collaborator |
---|---|
UCB BIOSCIENCES, Inc. | UCB Biopharma SRL |
United States, Argentina, Australia, Belgium, Brazil, Bulgaria, China, Colombia, Croatia, Czechia, Estonia, France, Georgia, Greece, Hungary, Israel, Italy, Korea, Republic of, Latvia, Lithuania, Mexico, Moldova, Republic of, Montenegro, Philippines, Poland, Portugal, Romania, Russian Federation, Serbia, Slovakia, Slovenia, Taiwan, Thailand, Ukraine, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) | An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. Treatment-emergent is defined as starting on or after the date of first dose of LCM in EP0034, and within 30 days of last dose. | From Week 0 to the End of Safety Follow-Up (up to Week 104) | |
Primary | Percentage of Participants With Serious TEAEs | A serious adverse event (SAE) must meet 1 or more of the following criteria: • Death, • Life-threatening (Life-threatening does not include a reaction that might have caused death had it occurred in a more severe form.), • Significant or persistent disability/incapacity, • Congenital anomaly/birth defect (including that occurring in a fetus), • Important medical event that, based upon appropriate medical judgment, may jeopardize the patient or participant and may require medical or surgical intervention to prevent 1 of the other outcomes listed in the definition of serious., • Initial inpatient hospitalization or prolongation of hospitalization. Treatment-emergent is defined as starting on or after the date of first dose of LCM in EP0034, and within 30 days of last dose. | From Week 0 to the End of Safety Follow-Up (up to Week 104) | |
Primary | Percentage of Participants With TEAEs Leading to Study Discontinuation | An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. AEs leading to study discontinuation. Treatment-emergent is defined as starting on or after the date of first dose of LCM in EP0034, and within 30 days of last dose. | From Week 0 to the End of Safety Follow-Up (up to Week 104) | |
Secondary | Percentage of Seizure-free Days During the Study | The number of seizure-free days was the total number of days within an interval for which daily diary data were available and no seizures were reported. The percentage of seizure-free days was computed as 100 times the number of seizure-free days in the interval divided by the number of days in the interval for which daily diary data were available. Percentage of seizure-free days was measured using data obtained from participant diaries from EP0034 and is presented for the overall Treatment only. | From Week 0 to End of Treatment (up to Week 96) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04595513 -
Stopping TSC Onset and Progression 2: Epilepsy Prevention in TSC Infants
|
Phase 1/Phase 2 | |
Completed |
NCT02909387 -
Adapting Project UPLIFT for Blacks in Georgia
|
N/A | |
Completed |
NCT05552924 -
Self Acupressure on Fatigue and Sleep Quality in Epilepsy Patients
|
N/A | |
Terminated |
NCT01668654 -
Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS
|
Phase 3 | |
Not yet recruiting |
NCT05068323 -
Impact of Interictal Epileptiform Activity on Some Cognitive Domains in Newly Diagnosed Epileptic Patients
|
N/A | |
Completed |
NCT03994718 -
Creative Arts II Study
|
N/A | |
Recruiting |
NCT04076449 -
Quantitative Susceptibility Biomarker and Brain Structural Property for Cerebral Cavernous Malformation Related Epilepsy
|
||
Completed |
NCT00782249 -
Trial Comparing Different Stimulation Paradigms in Patients Treated With Vagus Nerve Stimulation for Refractory Epilepsy
|
N/A | |
Completed |
NCT03683381 -
App-based Intervention for Treating Insomnia Among Patients With Epilepsy
|
N/A | |
Recruiting |
NCT05101161 -
Neurofeedback Using Implanted Deep Brain Stimulation Electrodes
|
N/A | |
Active, not recruiting |
NCT06034353 -
Impact of Pharmacist-led Cognitive Behavioral Intervention on Adherence and Quality of Life of Epileptic Patients
|
N/A | |
Recruiting |
NCT05769933 -
Bridging Gaps in the Neuroimaging Puzzle: New Ways to Image Brain Anatomy and Function in Health and Disease Using Electroencephalography and 7 Tesla Magnetic Resonance Imaging
|
||
Not yet recruiting |
NCT06408428 -
Glioma Intraoperative MicroElectroCorticoGraphy
|
N/A | |
Not yet recruiting |
NCT05559060 -
Comorbidities of Epilepsy(Cognitive and Psychiatric Dysfunction)
|
||
Completed |
NCT02977208 -
Impact of Polymorphisms of OCT2 and OCTN1 on the Kinetic Disposition of Gabapentin in Patients Undergoing Chronic Use
|
Phase 4 | |
Completed |
NCT02646631 -
Behavioral and Educational Tools to Improve Epilepsy Care
|
N/A | |
Completed |
NCT02952456 -
Phenomenological Approach of Epilepsy in Patients With Epilepsy
|
||
Recruiting |
NCT02539134 -
TAK-935 Multiple Rising Dose Study in Healthy Participants
|
Phase 1 | |
Completed |
NCT02491073 -
Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements for Subjects Treated With Eslicarbazeine Acetate (ESL)
|
N/A | |
Terminated |
NCT02757547 -
Transcranial Magnetic Stimulation for Epilepsy
|
N/A |